“Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)”. SKIN The Journal of Cutaneous Medicine 4, no. 5 (September 2, 2020): s49. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/1007.